BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cappella Medical Devices Ltd Expands its Distribution Network to the Middle East and Asia


10/13/2011 10:49:53 AM

GALWAY, Ireland--(BUSINESS WIRE)--Cappella Medical Devices Ltd (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, is delighted to announce that Doox Medica has been appointed as the exclusive distributor in Middle Eastern territories and the Sideguard® Coronary Stent system has been approved by the Saudi FDA. The Sideguard incorporates Cappella’s proprietary stent design and balloon delivery system and offers the interventional cardiologist a unique product solution for providing ostial protection and side branch preservation for a wide range of bifurcation lesions. Consistent with the strategy to accelerate commercialization in the emerging growth markets Cappella is also seeking market entry of its Sideguard product in India in the near term. These two important developments underline the commitment to expanding the global access to Cappella’s breakthrough bifurcation technology. The entry into Asia represents the next exciting phase of development. Cappella’s commitment to India will in the longer term extend to clinical trials of its next generation of products currently under development that will result in additional commercialization opportunities.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES